Ignota Labs’ core product is SAFEPATH, a platform that applies deep learning, cheminformatics and bioinformatics to uncover the molecular and biological causes of drug toxicity and generate actionable fixes. The company focuses on identifying promising drug candidates abandoned for safety reasons—often 80–90% of the way to success—and re-engineering them to shorten development timelines and reduce costs. Ignota has in‑licensed a first-in-class metabolic health asset, resolved its safety concerns with SAFEPATH, and validated findings in rodent models. That asset is a PDE9A inhibitor the company plans to advance into early-stage clinical trials and which the company says could improve the lives of ~1.2 billion post‑menopausal women. Ignota’s approach targets a major industry problem—drug safety failures block over 56% of drugs from reaching patients—and aims to unlock multibillion-dollar value from rescued therapies. The company will use recent financing to expand its pipeline by acquiring additional distressed assets and progressing its lead program toward the clinic.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2025